Mallinckrodt, page-4

• 2000 – Tyco International acquires Mallinckrodt^[13]
• 2007 – Tyco Healthcare spins off and becomes Covidien, an independent company.^[14] The healthcare business units were spun off under the name Covidien.^[15]
• 2011 – Covidien announces plans to spin off Mallinckrodt Pharmaceuticals as a standalone public company^[16][17] Mallinckrodt Plc was officially separated as of June 28, 2013. Trading of regular shares of the company’s stock on the New York Stock Exchange began on July 1, 2013, under the ticker symbol MNK.^[2]
• 2012 – Mallinckrodt announces acquisition of CNS Therapeutics for $100 million^[18]
• 2013 – Mallinckrodt spins off from Covidien and begins trading under ticker symbol MNK^[2]
• 2014 – Acquires Cadence Pharmaceuticals^[19] and Questcor Pharmaceuticals;^[20] joins S&P 500^[21]
• 2015 – Acquires Ikaria Inc. for $2.3 billion^[22]
• 2015 – Acquires Therakos for $1.325 billion^[23]
• 2015 - Sold the Contrast Media and Deliver Systems portion of the portfolio to Guerbet for $270M cash with a loan financed by BNP Paribas ^[24]
• 2016 – Acquires regeneratitive medicine company Stratatech^[25]